Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON
Objective We assessed adverse events and changes in forced vital capacity (FVC) in patients treated with open-label nintedanib over 148 weeks of SENSCIS-ON, the extension of the SENSCIS trial.Methods Adverse events and changes in FVC over 148 weeks of SENSCIS-ON were assessed in patients who receive...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BMJ Publishing Group
2025-02-01
|
| Reeks: | RMD Open |
| Online toegang: | https://rmdopen.bmj.com/content/11/1/e005086.full |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|